New study looks at FDA's use of social media to communicate on drug safety
A new study looking at the FDA use of social media to communicate about drug safety finds that the agency could improve its impact by developing social media strategies and taking a more active role on web platforms.
The study, conducted by researchers at Harvard Medical School, Northeastern University, Boston Children’s Hospital and The Ohio State University, and funded by FDA’s Center for Drug Evaluation and Research, looks specifically at FDA’s use of social media following two drug safety communications (DSCs) for drugs containing zolpidem, the active ingredient in Ambien.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.